Events

The ability to get a vital medicine delivered to the right patient in the optimal site of care, at the right time and price, is called “market access.” Market access is important for bio-entrepreneurs to appreciate even at the earliest stages, because, beyond a technology’s meaningful improvement on standard of care, investors will expect a value proposition that considers several crucial elements of market access. Your ability to answer their questions affects your ability to secure new/continued funding and maximize valuation. Join us to learn key insights from James Reilly and his colleagues at A3Access, who between them have 75+ years of hands-on experience in market access for US medicines.

Register for the Livestream

About the Speakers

James Reilly, Co-Founder, Managing Partner

28+ yrs. of executive biopharma experience.

James has over 28 years of diverse commercial leadership experience in biotechnology and healthcare. During this time, he held multiple executive internal and field-based leadership positions across market access and sales while at Genentech for 25 years. Key areas of responsibility included account management, distribution, access, pricing, contract strategy, managed care marketing, contract management, competitive selling, contract negotiation, and operations. He has significant experience in developing and executing innovative distribution and access strategies and has been involved in the successful launch of over 30 new medicines and hundreds of new indications across many therapeutic areas including Oncology, Neuroscience, Autoimmune Diseases, Hematology, Rare Diseases and Ophthalmology. James has also served as both a board member and Chairman for the HDA Research Foundation.

Prior to Genentech, he was responsible for strategy and contracting efforts for a 600-member, multi-specialty medical group.

James holds a B.S. in Health Science with a concentration in Healthcare Management from San Jose State University.

Steve Henck, MBA, Partner

30+ years of biopharma leadership experience

Having worked both within the supply chain and for Biopharma manufacturers, Steve brings 30+ years of biopharma business experience. He brings deep expertise in both the strategy and execution of biopharma commercialization with a specific focus on market access. Steve led many account management teams during his 17 year tenure with Genentech including Trade/Distribution, Payer, GPO, PBM, BioOncology, Federal Accounts, and he led a cross functional and innovative ecosystem. His diverse experience includes hiring, training, and deploying many of these teams. Contract strategy and negotiation are important fundamentals of account strategy and have been significant elements of each of Steve’s roles. He thoroughly enjoys all market access and commercialization related topics.

Steve has worked extensively in BioOncology, Rare Disease, Ophthalmology, Neurology, Rheumatology, Hematology, and Behavioral Health with products reimbursed through both medical and pharmacy benefits. He also spent time working for Deloitte and Touche, Cardinal Health, Takeda Pharmaceuticals, and Pardes Biosciences in both strategy and executive leadership roles. Steve holds an M.B.A., and a B.S. from The Ohio State University.

Dave Henderson, MBA, Co-Founder, Senior Partner

30+ yrs. of executive biopharma, venture & tech experience.

Dave has over 30 years of commercial, financial, and general management experience in life sciences and technology. During that time, he has held senior leadership positions in public companies including Biomarin and Genentech, and in emerging growth, venture-backed companies. Most recently, Dave was the Vice President of Global Commercial Operations at BioMarin where he was responsible for a broad array of commercial functions including US managed markets & trade, US hub operations, global price management, global launch sequencing & market prioritization, global revenue planning & business analytics, global customer order management, and commercial systems.

Over his tenure in biotechnology, he has supported therapies in rare disease, oncology, immunology, and ophthalmology. Dave has developed pricing strategies for chronic therapies and gene therapies. He has experience with all product life-cycle stages from pipeline to launch, through growth and maturity including generic competition. He has worked with distribution partners including specialty pharmacies and wholesalers in the US, and with full-service distribution partners and 3PLs outside of the US.

Dave holds a BS in Business Administration from the University of California, Berkeley, and an MBA from the JL Kellogg School of Management at Northwestern University. He also earned a certificate in Biotechnology for Business from Duke University.